Understanding the molecular mechanism of drug resistance of anti-HIV nucleosides by molecular modeling

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 164-186

  Chong, Youhoon ^a   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

3TC; AZT; D4 Nucleosides; Dioxolane Nucleosides; HIV 1 Reverse Transcriptase; Mechanism Of Resistance; Molecular Modeling; Mutants; Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Review

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ABACAVIR; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; MUTANT PROTEIN; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS DNA; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE;

BINDING AFFINITY; BINDING SITE; CALCULATION; CELL ACTIVITY; CONFORMATION; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG STRUCTURE; ENERGY; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DYNAMICS; MOLECULAR MODEL; MONTE CARLO METHOD; MUTATION; PHOSPHORYLATION; REVIEW; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; MULTIDRUG RESISTANCE; PROTEIN CONFORMATION;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; NUCLEOSIDES; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 2542484519     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1220     Document Type: Review

References (127)

1. Mitsuya H., K. J. Weinhold, P. A. Furman, M. H. St Clair, S. Nusinofff-Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry & S. Broder: 3′-Azido-3′-deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropicvirus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82, 7096-7100 (1985)
2. Coates J. A.V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron & C. R. Penn: The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit hiv replication in vitro. Antimicrob Agents Chemother 36, 202-205 (1992)
3. Mitsuya H. & S. Broder: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 83, 1911-1915 (1986)
4. Chu C. K., R. F. Schinazi, B. H. Arnold, D. L. Cannon, B. Doboszewski, V. B. Bhadti & Z. Gu: Comparative activity of 2′,3′-saturated and unsaturated pyrimidine and purine nucleosides against HIV-1 in peripheral blood mononuclear cells. Biochem Pharmacol 37, 3543-3548 (1988)
5. Lin T. -S., R. F. Schinazi & W. H. Prusoff: Potent and selective in-vitro activity of 3′-deoxythymidin-2′-ene(3′-deoxy- 27prime;,3′-didehydrothymidine) against human immunodefiency virus. Biochem Pharmacol 36, 2713-2718 (1987)
6. Daluge S. M., S. S. Good, M. B. Faletto, W. H. Miller & M. H. St Clair: 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 41, 1082-1093 (1997)
7. Arimilli M. N., C. U. Kim, J. Dougherty, A. Mulato, R. Oliyai, J. P. Shaw, K. C. Cundy & N. Bischofberger: Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-[(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 8, 557-564 (1997)
8. Merluzzi V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. -K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup & J. L. Sullivan: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411-1413 (1990)
9. Romero D. L., R. A. Morge, M. J. Genin, C. Biles, M. Busso, L. Resnick, I. W. Althaus, R. Reusser, R. C. Thomas & W. G. Tarpley: Bis(heteroaryl)piperzine(BHAP) RT inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of monomethanesulfonate(U-90152S). J Med Chem 36, 1505-1508 (1993)
10. Young S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'brien, R. G. Ball, S. K. Balani, J. H. Lin, W. J. Long, V. W. Byrnes & E. A. Emini: L-743,726(DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39, 2602-2605 (1995)
11. Huang H., R. Chopra, G. L. Verdine & S. C. Harrison: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282, 1669-1675 (1998)
12. Smith M. B. K., C. J. Michejda, S. H. Hughes, P. L. Boyer, P. A. J. Janssen, K. Andries, R. W. Buckheit & R. H. S. Smith, Jr.: Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action. Protein Eng 10, 1379-1383 (1997)
13. Huber H. E., J. M. McCoy, J. S. Seehra & C. C. Richardson: Human immunodeficiency virus-1 reverse transcriptase-template binding, processivity, strand displacement synthesis, and template switching. J Biol Chem 264, 4669-4678 (1989)
14. Hao Z., D. A. Cooney, N. R. Hartman, C. F. Perno, A. Fridland, A. L. Devico, M. G. Sarngadharan, S. Broder & D. G. Johns: Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 34, 431-435 (1988)
15. McGowan J. J., J. E. Tomaszewski, J. Cardock, D. Hoth, C. K. Grieshaber, S. Broder & H. Mitsuya: Overview of the preclinical development of an antiretroviral drug, 2′,3′-dideoxyinosine. Rev Infect Dis 12, S513-S521 (1990)
16. Zimmerman T. P., W. B. Mahoney & K. L. Prus: 3′-Azido-3′- deoxythymine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 262, 5748-5754 (1987)
17. Arner E. S. J. & S. Eriksson. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67, 155-186 (1995)
18. Furman P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. Nusinoff-Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya & D. W. Barry: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83, 8333-8337 (1986)
19. Johnson M. A., G. Ahluwalia, M. C. Connelly, D. A. Cooney, S. Broder, D. G. Johns & A. Fridland: Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J Biol Chem 263, 15354-15357 (1988)
20. Johnson M. A. & A. Fridland: Phosphorylation of 2′,3′- dideoxyinosine by cytosolic 5′-nucleotidase of human lympoid cells. Mol Pharmacol 36, 291-295 (1989)
21. Keller P. M., S. A. McKee & J. A. Fyfe: Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem 260, 8664-8667 (1985)
22. Chang C. N., V. Skalski, J. H. Zhou & Y. C. Cheng: Biochemical Pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 267, 22414-22420 (1992)
23. Verri A., F. Focher, G. Priori, G. Gosselin, J. -L. Imbach, M. Capobianco, A. Garbesi & S. Spadari: Lack of enantioselectivityof human 2′-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol 51, 132-138 (1997)
24. Gaubert G., G. Gosselin, V. Boudou, J. -L. Imbach, S. Eriksson & G. Maury: Low enantioselectivities of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2′-deoxyadenosine, 2′-deoxyguanosine and their analogs. Biochimie 81, 1041-1047 (1999)
25. Nennett L. L., P. W. Allan, G. Arnett, Y. F. Shealy, D. S. Shewach, W. S. Mason, I. Fourel & W. P. Parker: Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2′-deoxyguanosine: substrate activity with deoxycytidine kinase, mithchondrial deoxyguanosine kinase and 5′-nucleotidase. Antimicrob Agents Chemother 42, 1045-1051 (1998)
26. Goody R. S., B. Müller & T. Restle: Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett 291, 1-5 (1991)
27. St. Clair M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp & B. A. Larder: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559 (1991)
28. Kati W. M., K. A. Johnson, L. F. Jerva & K. S. Anderson. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem 267, 25988-25997 (1992)
29. Hsieh J. C., S. Zinnen & P. Modrich: Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J Biol Chem 268, 24607-24613 (1993)
30. Reardon J. E. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J Biol Chem 268, 8743-8751 (1993)
31. Wöhrl B. M., R. Krebs, R. S. Goody & T. Restle: Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate. J Mol Biol 292, 333-344 (1999)
32. Rittinger K., G. Divita & R. S. Goody: Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 92, 8046-8049 (1995)
33. Cheng Y. -C., G. E. Dutchman, M. K. Bastow, M. G. Sarngadharan & R. Y. C. Ting: Human immunodeficiency virus reverse transcriptase: general properties and its interaction with nucleoside triphsophate analogues. J Biol Chem 262, 2187-2189 (1987)
34. Reardon J. E. & W. H. Miller: Human immunodeficiency virus reverse transcriptase: substrate and inhibitor kinetics with thymidine 5′-triphsophate and 3′-azido-3′-deoxythumidine 5′-triphosphate. J Biol Chem 265, 20302-20307 (1990)
35. St. Clair M. H., C. A. Richards, T. Spector, K. J. Weinhold, W. H. Miller, A. J. Langlois & P. A. Furman: 3′-Azido-3′- deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31, 1972-1977 (1987)
36. Pauwels R., J. Balzarinin, D. Schols, M. Baba, A. J. Desmyter, I. Rosenberg, A. Holy & E. De Clercq: Phosphonyl-methoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 32, 1025-1030 (1988)
37. Preston B. D., B. J. Poiesz & L. A. Loeb: Fidelity of HIV-1 reverse transcriptase. Science 242, 1168-1171 (1988)
38. Hart G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Boehme & J. M. Cameron: Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphsophate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerase alpha, beta and gamma. Antimicrob Agents Chemother 36, 1688-1694 (1992)
39. Huang P., D. Farquhar & W. Plunkett: Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 265, 11914-11918 (1990)
40. Orr D. C., H. T. Figueiredo, C. -L. Mo, C. R. Penn & J. M. Cameron: DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′,3′-didehydro-2′, 3′-dideoxyguanosine triphosphate. J Biol Chem 267, 4177-4182 (1992)
41. Wilson J. E., J. L. Martin, K. Borroto-Esoda, S. Hopkins, G. Painter, D. C. Liotta & P. A. Furman: The 5′-triphosphates of the (-) and (+) enantiomers of cis-5-flujoro-1-[2-(hydroxymethyl)-1,3-oxathilane-5-yl] cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37, 1720-1722 (1993)
42. Reardon J. E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31, 4473-4479 (1992)
43. Rodgers D. W., S. J. Gamblin, B. A. Harris, S. Ray, J. S. Culp, B. Hellmig, D. Woolf, C. Debouck & S. Harrison: The structure of the unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92, 1222-1226 (1995)
44. Hsiou Y., J. Ding, K. Das, A. D. Clark Jr, S. H. Hughes & E. Arnold: Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4, 853-860 (1996)
45. Jacobo-Molina A., J. Ding, R. G. Nanni, A. D. Clark Jr., X. D. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes & E. Arnold: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci USA 90, 6320-6324 (1993)
46. Ding J. P., K. Das, Y. Hsiou, S. G. Sarafianos, A. D. Clark Jr., A. Jacobo-Molina, C. Tantillo, S. H. Hughes & E. Arnold: Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J Mol Biol 284, 1095-1111 (1998)
47. Le Grice S. F. J: Human immunodeficiency virus reverse transcriptase. In: Reverse Transcriptase. Eds: Skalka, A. M., Goff, S. P. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1994)
48. Ollis D. L., P. Brick, R. Hamlin, Ng. Xuong & T. A. Steitz: Structure of large fragment of Escherichia-Coli DNA-polymerase-I complexed with DTMP. Nature 313, 762-766 (1985)
49. Kohlstaedt L. A., J. Wang, J. M. Friedman, P. A. Rice & T. A. Steitz: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992)
50. Wang J., S. J. Smerdon, J. Jager, L. A. Kohlstaedt, P. A. Rice, J. M. Friedman & T. A. Steitz: Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 91, 7242-7246 (1994)
51. Ren J. S., R. Esnouf, E. Carman, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart & D. Stammers: High-resolution structures of HIV-1 RT from 4 RT-inhibitor complexes. Nature Struct Biol 2, 293-302 (1995)
52. Ding J. P., K. Das, H. Moereels, L. Koymans, K. Andries, P. A. J. Janssen, S. H. Hughes & E. Arnold: Structure of HIV-1 RT/TIBO R-86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct Biol 2, 407-415 (1995)
53. Steitz T. A: DNA polymerases: structural diversity and common mechanisms. J Biol Chem 274, 17395-17398 (1999)
54. Boulerice F., S. Bour, R. Geleziunas, A. Lvovich & M. A. Wainberg: High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U937 cells. J Virol 64, 1745-1755 (1990)
55. Larder B. A., G. Darby & D. Richman: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989)
56. Larder B. A. & S. D. Kemp: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science 246, 1155-1158 (1989)
57. Larder B. A., S. D. Kemp & D. J. M. Purifoy: Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci USA 86, 4803-4807 (1989)
58. Richman D. D: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 37, 1207-1213 (1993)
59. Rooke R., M. Tremblay & M. A. Wainberg: AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology 176, 205-215 (1990)
60. Wainberg M. A., Z. Gu, Q. Gao, E. Arts, R. Geleziunas, S. Bour, R. Beaulieu, C. Tsoukas, J. Singer & J. Montaner: Clinical correlates and molecular basis of HIV drug resistance. J Acquired Immune Defic Syndr 6 (Suppl.1), S36-S46 (1993)
61. Fitzgibbon J. E., R. M.,Howell, C. A. Haberzettl, S. J.,Sperber, D. J. Gocke & D. T. Dubin: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 36, 153-157 (1992)
62. Schinazi R. F., R. M. Lloyd, M. -H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi & J. W. Mellors: Characterization of human immunodeficiency viruses resistant to oxathiloane-cytosine nucleosides. Antimicorb Agents Chemother 37, 875-881 (1993)
63. St. Clair M. H., J. L. Martin, G. TudorWilliams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp & B. A. Larder: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559 (1991)
64. Gao Q., Z. Gu, M. A. Parniak, X. Li & M. A. Wainberg: In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 66, 12-19 (1992)
65. Gao Q., Z. Gu, J. M. Cameron, N. Cammack, C. Boucher & M. A. Wainberg: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxycytidine confers high-level resistance against the (-) enantiomer of 2′,3′-dideoxy-3′- thiacytidine. Antimicrob Agents Chemother 37, 1390-1392 (1993)
66. Gu Z., Q. Gao, X. Li, M. A. Parniak & M. A. Wainberg: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine. J Virol 66, 7128-7135 (1992)
67. Larder B. A., K. E. Coates & S. D. Kemp: Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 65, 5232-5236 (1991)
68. Moyle G. J.: Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis 5, 170-182 (1995)
69. Lacey S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp & B. A. Larder: Biochemical studies on the reverse transcriptase and RNAse H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 267, 15789-15794 (1992)
70. Sluis-Cremer N., D. Arion & M. A. Parniak: Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors, (NRTIs). Cell Mol Life Sci 57, 1408-1422 (2000)
71. Chong Y., K. Borroto-Esoda, P. A. Furman, R. F. Schinazi & C. K. Chu: Molecular mechanism of DAPD/DXG against zidovudine-and lamivudine-drug resistant mutants: a molecular modeling approach. Antivir Chem Chemother 13, 115-128 (2002)
72. Choo H., Y. Chong & C. K. Chu: The role of 2′,3′- unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V). Bioorg Med Chem Lett 13, 1993-1996 (2003)
73. Chong Y. & C. K. Chu: Understanding the unique mechanism of L-FMAU (Clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg Med Chem Lett 12, 3459-3462 (2002)
74. Lee K. & C. K. Chu: Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob Agents Chemother 45, 138-144 (2001)
75. Birnbaum G. I., J. Giziewicz, E. J. Gabe, T. S. Lin & W. H. Prusoff: Structure and conformation of 3′-azido-3′-deoxythymidine (AZT), an inhibitor of the HIV (AIDS) virus. Can J Chem 65, 2135-2139 (1987)
76. Birnbaum G. I., T. S. Lin & W. H. Prusoff: Unusual structural features of 2′,3′-dideoxycytidine, an inhibitor of the HIV (AIDS) virus. Biochem Biophys Res Commun 151, 608-614 (1988)
77. Van roey P., W. A. Pangborn, R. F. Schinazi, G. Painter & D. C. Liotta: Absolute-configuration of the antiviral agent (-)-cis-5-fluoro-1-[2- hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antivir Chem Chemother 4, 369-375 (1993)
78. Van roey P., E. W. Taylor, C. K. Chu & R. F. Schinazi: Conformational-analysis of 2′,3′-didehydro-2′,3′- dideoxypyrimidine nucleosides. J Am Chem Soc 115, 5365-5371 (1993)
79. Kim H. O., S. K. Ahn, A. J. Alves, J. W. Beach, L. S. Jeong, B. G. Choi, P. Van roey, R. F. Schinazi & C. K. Chu: Asymmetric synthesis of 1,3-dioxolane pyrimidine nucleosides and their anti-HIV activity. J Med Chem 35, 1987-1995 (1992)
80. Gästeiger J. & M. Marsili: Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges. Tetrahedron 36, 3219-3228 (1980)
81. Purcell W. P. & J. A. Singer: A brief review and table of semiempirical parameters used in Hückel molecular orbital method. J Chem Eng Data 12, 235-246 (1967)
82. Blaney J. M., P. K. Weiner, A. Dearing, P. A. Kollman, E. C. Jorgensen, S. J. Oatley, J. M. Burridge & C. C. F. Blake: Molecular mechanics simulation of protein ligand interactions - Binding of thyroid-hormone analogs to pre-albumin. J Am Chem Soc 104, 6424-6434 (1982)
83. Wipff G., A. Dearing, P. K. Weiner, J. M. Blaney & P. A. Kollman: Molecular mechanics studies of enzyme-substrate interactions - The interaction of L-N-acetylryptophanamide and D-N-acetyltryptophanamide with alpha-chymotrypsin. J Am Chem Soc 105, 997-1005 (1983)
84. Cornell W. D., P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz, D. M. Ferguson, D. C. Spellmeyer, T. Fox, J. W. Caldwell & P. A. Kollman: A 2nd generation force-field for the simulation of proteins, nucleic acids, and organic-molecules. J Am Chem Soc 117, 5179-5197 (1995)
85. Dunitz J. D. & R. Taylor: Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 3, 89-98 (1997)
86. Weiner S. J., P. A. Kollman, D. T. Nguyen & D. A. Case: An all atom force-field for simulations of proteins and nucleic-acids. J Comp Chem 7, 230-252 (1986)
87. Argos P.: A sequence motif in many polymerases. Nucleic Acids Res 16, 9909-9916 (1988)
88. Feng J. Y. & K. S. Anderson: Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38, 55-63 (1999)
89. Feng J. Y. & K. S. Anderson: Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resislant mutant (M184V) of HIV-1 reverse transcriptase. Biochemistry 38, 9440-9448 (1999)
90. Krebs R., U. Immendörfer, S. H. Thrall, B. M. Wohrl & R. S. Goody: Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3TC. Biochemistry 36, 10292-10300 (1997)
91. Quan Y., Z. Gu, X. Li, Z. Li, C. D. Morrow & M. A. Wainberg: Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)-2′,3′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 70, 5642-5646 (1996)
92. Sarafianos S. G., K. Das, A. D. Clark Jr., J. Ding, P. Boyer, S. H. Hughes & E. Arnold: Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 96, 10027-10032 (1999)
93. Kavlick M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, R. Yarchoan & H. Mitsuya: Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir Res 71, 6928-6934 (1995)
94. Tisdale M., S. D. Kemp, N. R. Parry & B. A. Larder: Rapid in vitro selection of human immunodeficiency virus type 1 rsistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90, 5653-5656 (1993)
95. Furman P. A., J. Jeffrey, L. L. Keifer, J. Y. Feng, J. S. Anderson, K. Borroto-Esoda, E. Hill, W. C. Copeland, C. K. Chu, J. -P. Sommadossi, I. Liberman, R. F. Schinazi & G. R. Painter: Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother 45, 158-165 (2001)
96. Stoddart C. A., M. E. Moreno, V. D. Linquist-Stepps, C. Bare, M. Bogan, A. Gobbi, R. W. Buckheit Jr., J. Bedard, R. F. Rando & J. M. McCune: Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother 44, 783-786 (2000)
97. Robbins B. L., R. V. Srinivas, C. Kim, N. Bischofberger & A. Fridland: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42, 612-617 (1998)
98. Daluge S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St.Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett & T. A. Krenitsky: 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 41, 1082-1093 (1997)
99. Schinazi R. F., J. Mellors, H. Bazmi, S. Diamond, S. Garber, K. Gallagher, R. Geleziunas, R. Klabe, M. Pierce, M. Rayner, J. -T. Wu, H. Zhang, J. Hammond, L. Bacheler, D. J. Manion, M. J. Otto, L. Stuyver, G. Trainor, D. C. Liotta & S. Erickson-Viitanen: DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob Agents Chemother 46, 1394-1401 (2002)
100. Lee K., Y. Choi, G. Gumina, W. Zhou, R. F. Schinazi & C. K. Chu: Structure-activity relationships of 2′-fluoro-2 ′,3′- unsaturated D-nucleosides as anti-HIV-1 agents. J Med Chem 45, 1313-1320 (2002)
101. Chong Y., H. Choo, Y. Choi, J. Mathew, R. F. Schinazi & C. K. Chu: Stereoselective synthesis and antiviral activity of D-2′,3′- didehydro-2′,3′-dideoxy-2′-fluoro-4′-thionucleosides. J Med Chem 45, 4888-4898 (2002)
102. Lee K., Y. Choi, E. Gullen, S. Schlueter-Wirtz, R. F. Schinazi, Y. C. Cheng & C. K. Chu: Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleosides. J Med Chem 42, 1320-1328 (1999)
103. Choo H., Y. Chong, Y. Choi, J. Mathew, R. F. Schinazi & C. K. Chu: Synthesis, anti-HIV activity, and molecular mechanism of drug resistance of L-2′,3′-didehydro-2′,3′-dideoxy-2′-fluoro- 4′-thionucleosides. J Med Chem 46, 389-398 (2003)
104. Chong Y., G. Gumina, J. S. Mathew, R. F. Schinazi & C. K. Chu: L-2′,3′-Didehydro-2′,3′-dideoxy-3′- fluoronucleosides: Synthesis, Anti-HIV Activity, Chemical and Enzymatic Stability and the Mechanism of Resistance. J Med Chem 46, 3245-3256 (2003)
105. Gumina G., Y. Chong, W. Zhou, R. F. Schinazi & C. K. Chu: Synthesis, Structure-Activity Relationships of D-and L- 3′-Fluoro-2′,3′- Unsaturated Nucleosides as Anti-HIV Agents. Antivir Res 57, A14 (2003)
106. Zhu W., H. Choo, Y. Chong, W. Zhou, R. F. Schinazi & C. K. Chu: Synthesis and Anti-HIV Activities of L-beta-2′,3′-Didehydro- 2′,3′-Dideoxy- 3′-Fuoro-4′-Thio-Nucleosides. Antivir Res 57, A14 (2003)
107. Zhu W., Y. Chong, H. Choo, R. F. Schinazi & C. K. Chu: D- and L- 2′,3′-Didehydro-2′,3′-dideoxy-3′-fluoro-4′- thionucleosides: Synthesis, Anti-HIV Activity and the Mechanism of Resistance. J Med Chem Submitted for Publication (2003)
108. Chong Y. & C. K. Chu: Functional 3′-oxygen atom locates the D-dioxolane nucleoside triphosphates away from Va1184 to avoid steric hindrance. Antivir Chem Chemother Submitted for publication (2003)
109. Gu Z., M. A. Wainberg, N. Nguyen-Ba, L. L'Heureux, J. M. De Muys, T. L. Bowlin & R. F. Rando: Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 43, 2376-2382 (1999)
110. Furman P. A., J. Jeffrey, L. L. Keifer, J. Y. Feng, J. S. Anderson, K. Borroto-Esoda, E. Hill, W. Copeland, C. K. Chu, J. -P. Sommadossi, I. Liberman, R. F. Schinazi & G. R. Painter: Mechanism of action of 1-beta-D-2,6- diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother 45, 158-165 (2001)
111. Larder B. A., S. D. Kemp & P. R. Harrigan: Potential mechanisim for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699 (1995)
112. Kellam P., C. A. Boucher & B. A. Larder: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89, 1934-1938 (1992)
113. Harrigan P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli & B. A. Larder: Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 70, 5930-5934 (1996)
114. Hooker D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Aronld & N. J. Deacon: An in vivo mutation fro leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 70, 8010-8018 (1996)
115. Carroll S. S., J. Geib, D. B. Olsen, M. Stahlhut, J. A. Shafer & L. C. Kuo: Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 332, 2113-2120 (1994)
116. Kerr S. G. & K. S. Anderson: Pre-steady-state kinetic characterization of WILD-TYPE and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36, 14064-14070 (1997)
117. Arion D. & M. A. Parniak: HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Res Updates 2, 91-95 (1999)
118. Arion D., N. Kaushik, S. McCormick, G. Borkow & M. A. Parniak: Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908-15917 (1998)
119. Boyer P. L., S. G. Sarafianos, E. Arnold & S. H. Hughes: Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 75, 4832-4842 (2001)
120. Meyer P. R., S. E. Matsuura, A. G. So & W. A. Scott: Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide dependent mechanism. Proc Natl Acad Sci USA 95, 13471-13476 (1998)
121. Meyer P. R., S. E. Matsuura, A. M. Mian, A. G. So & W. A. Scott: A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43 (1999)
122. Barshop B. A., D. T. Adamson, D. C. Vellom, R. Rosen, B. L. Epstein & J. E. Seegmiller: Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleolide adenylyl transferase or adenosine-5′-triphosphate sulfurylase. Anal Bioch 197, 266-272 (1991)
123. Painter G. R., A. E. Aulabaugh & C. W. Andrew: A comparison of the conformations of the 5′-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase. Biochem Biophys Res Commun 191, 1166-1171 (1993)
124. Larder B. A. & D. K. Stammers: Closing in on HIV drug resistance. Nature Struct Biol 6, 103-106 (1999)
125. Boyer P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold & S. H. Hughes: Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length-the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci USA 91, 4882-4886 (1994)
126. Iversen A. F. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro & T. C.Merigan: Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70, 1086-1090 (1996)
127. Shirasaka T., M. F. Kavlick, T. Ueno, W. -Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan & H. Mitsuya: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92, 2398-2402 (1995)